DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183499

Monitoring effects of atenolol versus olmesartan medoxomil on metabolic parameters

Ranjodh Jeet Singh, Kanika Kohli, Parveen Gupta, Ashwani Kumar Gupta

Abstract


Background: The increase in CVS morbidity and mortality could be significantly reduced by control of SBP and DBP, as well as reduction in Hyperlipidemia.

Methods: The patients of stage-1 HTN with either sex according to JNC VII criteria were included and were followed up every 2 weeks from baseline upto 12 weeks. The randomized patients were divided into two groups to receive beta blocker viz. Atenolol 50 mg (group A, N=50) and ARB Olmesartan medoxomil 40 mg (group B, N=50).

Results: The average Total cholesterol measured among Group A subjects was significantly increased by 1.8% by the end of 12th week whereas the average cholesterol measured among Group B subjects at baseline period was reduced by 7.9% after 12 weeks therapy. The average HDL measured among Group A subjects at baseline period significantly reduces by 5.9% by the end of 12th week whereas the HDL levels measured among Group B subjects at baseline period was significantly increased by after 12 weeks therapy. The average Triglyceride (TG) levels measured among Group A subjects at baseline period was significantly increased by 12.4% by the end of 12th week whereas the Triglyceride (TG) levels measured among Group B subjects at baseline period was significantly reduced by 9.5% after 12 weeks therapy. The average LDL levels measured among Group A subjects at baseline period was significantly increased by 1.5% by the end of 12thweek whereas the average LDL measured among Group B subjects at baseline period was significantly reduced by 11.2% to after 12 weeks therapy. The average VLDL levels measured among Group A subjects at baseline period was significantly increased by 12.4% by the end of 12th week whereas the average VLDL measured among Group B subjects at baseline period was significantly reduced by 9.5% after 12 weeks therapy.

Conclusions: ARB- Olmesartan medoxomil is a better drug than beta blocker-Atenolol as it leads to greater deduction in lipid profile.


Keywords


Atenolol, CVD, COPD, DBP, HCTZ, HTN, Stage-1 HTN

Full Text:

PDF

References


Elkum N,Al-Arouj M, Sharifi M, Bennakhi A, Behbehani K, .Cardiovascular disease risk factors in the South Asian population :a cross-sectional study. Diabet Med. 2014 May; 31(5):531-9.

Stafylas PC, Sarafidis PA. Carvedilol in HTN treatment. Vasc Health Risk Manag. 2008 February; 4(1):23-30.

Chobanian AV, Bakris GL, Cushman WC, Black HR Green LA, Izzo JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC report. JAMA. 2003;289(19):2560-72.

Bundgaard M, Jarbol DE, Paulsen MS, Jacobsen JL, Pedersen ML. Prevalence of the use of antihypertensive medications in Greenland: a study of quality of care amongst patients treated with antihypertensive drugs. Int J Circumpolar Health. 2012;71:10.3402.

Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008 May 3;371(9623):1513-8.

Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology. Circulation. 2000 Jan 25;101(3):329-35.

Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004 February;18(2):73-8.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.

Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J. 1989 Apr 29;298(6681):1152-7.

Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology. 2007 Apr 1;12(2):147-53.

Leren P. Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties. Am J Med. 1987 Jan 5;82(1A):31-5.

Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vascular health and risk management. 2010;6:113-33.

Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Current Med Res Opin. 2010 Mar 1;26(3):615-29.